The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Topoisomerase I inhibitors: Review and update
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wall, M. E., Wani, M. C., Cook, C. E., Palmer, K. H., McPhail, A. T., & Sim, G. A. (1966) · Journal of the American Chemical Society · doi:10.1021/ja00968a057 · Cited by 2,258
Wang, J. C. (1985) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.54.070185.003313 · Cited by 1,540
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.
ten Bokkel Huinink, W., Gore, M., Carmichael, J., Gordon, A., Malfetano, J., Hudson, I., Broom, C., Scarabelli, C., Davidson, N., Spanczynski, M., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2183 · Cited by 663
DNA Topoisomerase I—Targeted Chemotherapy of Human Colon Cancer in Xenografts
Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R., & Potmesil, M. (1989) · Science · doi:10.1126/science.2555920 · Cited by 650
Kingsbury, W. D., Boehm, J. C., Jakas, D. R., Holden, K. G., Hecht, S. M., Gallagher, G., Caranfa, M. J., McCabe, F. L., Faucette, L. F., Johnson, R. K., et al. (1991) · Journal of Medicinal Chemistry · doi:10.1021/jm00105a017 · Cited by 518
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Vokes, E. E., & Ratain, M. J. (1994) · PubMed · Cited by 501
Ardizzoni, A., Hansen, H., Dombernowsky, P., Gamucci, T., Kaplan, S., Postmus, P., Giaccone, G., Schaefer, B., Wanders, J., & Verweij, J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.2090 · Cited by 480
Rougier, P., Bugat, R., Douillard, J. Y., Culine, S., Suc, E., Brunet, P., Becouarn, Y., Ychou, M., Marty, M., Extra, J. M., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.251 · Cited by 434
Kunimoto, T., Nitta, K., Tanaka, T., Uehara, N., Baba, H., Takeuchi, M., YOKOKURA, T., Sawada, S., Miyasaka, T., & Mutai, M. (1987) · PubMed · Cited by 410
Creemers, G. J., Bolis, G., Gore, M., Scarfone, G., Lacave, A. J., Guastalla, J. P., Despax, R., Favalli, G., Kreinberg, R., Van Belle, S., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.12.3056 · Cited by 377
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
Rowinsky, E. K., Grochow, L. B., Hendricks, C. B., Ettinger, D. S., Forastiere, A. A., Hurowitz, L. A., McGuire, W. P., Sartorius, S. E., Lubejko, B. G., & Kaufmann, S. H. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.647 · Cited by 353
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
Rothenberg, M. L., Eckardt, J. R., Kuhn, J. G., Burris, H. A., Nelson, J., Hilsenbeck, S. G., Rodriguez, G. I., Thurman, A. M., Smith, L. S., Eckhardt, S. G., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.4.1128 · Cited by 352
Self-citationIrinotecan is an active agent in untreated patients with metastatic colorectal cancer.
Conti, J. A., Kemeny, N. E., Saltz, L. B., Huang, Y., Tong, W. P., Chou, T. C., Sun, M., Pulliam, S., & Gonzalez, C. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.709 · Cited by 344
Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin.
Eng, W. K., Faucette, L., Johnson, R. K., & Sternglanz, R. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10121-1 · Cited by 325
Muggia, F. M., Creaven, P. J., Hansen, H. H., Cohen, M. H., & Selawry, O. S. (1972) · PubMed · Cited by 312
Morris, E. J., & Geller, H. M. (1996) · The Journal of cell biology · doi:10.1083/jcb.134.3.757 · Cited by 306
Phase I and pharmacokinetic trial of weekly CPT-11.
Rothenberg, M. L., Kuhn, J. G., Burris, H. A., Nelson, J., Eckardt, J. R., Tristan-Morales, M., Hilsenbeck, S. G., Weiss, G. R., Smith, L. S., & Rodriguez, G. I. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.11.2194 · Cited by 301
Self-citationTanizawa, A., Fujimori, A., Fujimori, Y., & Pommier, Y. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.11.836 · Cited by 300
Abigerges, D., Chabot, G. G., Armand, J. P., Hérait, P., Gouyette, A., & Gandia, D. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.210 · Cited by 299
Negoro, S., Fukuoka, M., Masuda, N., Takada, M., Kusunoki, Y., Matsui, K., Takifuji, N., Kudoh, S., Niitani, H., & Taguchi, T. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.16.1164 · Cited by 274
Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer.
Moertel, C. G., Schutt, A. J., Reitemeier, R. J., et al. (1972) · PubMed · Cited by 274
DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors.
Chen, A. Y., Yu, C., Gatto, B., & Liu, L. F. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8131 · Cited by 268
Bjornsti, M., Benedetti, P., Viglianti, G. A., & Wang, J. C. (1989) · PubMed · Cited by 264
Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).
Gottlieb, J. A., Guarino, A. M., CALL, J. B., Oliverio, V. T., & Block, J. B. (1970) · PubMed · Cited by 249
Kudelka, A. P., Tresukosol, D., Edwards, C. L., Freedman, R. S., Levenback, C., Chantarawiroj, P., Gonzalez de Leon, C., Kim, E. E., Madden, T., Wallin, B., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.5.1552 · Cited by 246
Husain, I., Mohler, J. L., Seigler, H. F., & Besterman, J. M. (1994) · PubMed · Cited by 244
Sugimoto, Y., Tsukahara, S., Oh‐hara, T., Isoe, T., & TSURUO, T. (1990) · PubMed · Cited by 223
Li, C. J., Averboukh, L., & Pardee, A. B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41552-9 · Cited by 219
Hendricks, C. B., Rowinsky, E. K., Grochow, L. B., Donehower, R. C., & Kaufmann, S. H. (1992) · PubMed · Cited by 210
Schiller, J. H., Kim, K., Hutson, P., DeVore, R., Glick, J., Stewart, J., & Johnson, D. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.8.2345 · Cited by 208
Tishler, R. B., Calderwood, S. K., Coleman, C. N., & Price, B. D. (1993) · PubMed · Cited by 200
Rowinsky, E. K., Grochow, L. B., Ettinger, D. S., Sartorius, S. E., Lubejko, B. G., Chen, T. L., Rock, M. K., & Donehower, R. C. (1994) · PubMed · Cited by 194
Irinotecan (CPT-11) and Characteristic Mucosal Changes in the Mouse Ileum and Cecum
Ikuno, N., Soda, H., Watanabe, M., & Oka, M. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.24.1876 · Cited by 187
Camptothecins New Anticancer Agents
Potmĕsil, M., & Pinedo, H. M. (1994) · Medical Entomology and Zoology · Cited by 179
Wagener, D. J. T., Verdonk, H. E. R., Dirix, L. Y., Catimel, G., Siegenthaler, P., Buitenhuis, M., Mathieu-Boué, A., & Verweij, J. (1995) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a059107 · Cited by 178
Chabot, G. G., Abigerges, D., Catimel, G., Culine, S., de Forni, M., Extra, J.-M., Mahjoubi, M., Hérait, P., Armand, J.-P., Bugat, R., et al. (1995) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a059109 · Cited by 173
Burris, H. A., Hanauske, A.-R., Johnson, R. K., Marshall, M. H., Kuhn, J. G., Hilsenbeck, S. G., & Von Hoff, D. D. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.23.1816 · Cited by 166
Hochster, H., Liebes, L., Speyer, J., Sorich, J., Taubes, B., Oratz, R., Wernz, J., Chachoua, A., Raphael, B., & Vinci, R. Z. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.3.553 · Cited by 162
Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells.
Chen, A. Y., Yu, C., Potmĕsil, M., et al. (1991) · PubMed · Cited by 157
Forni, M. D., Bugat, R., Chabot, G. G., Culine, S., Extra, J.-M., Gouyette, A., Madelaine, I., Marty, M. E., & Mathieu-Boué, A. (1994) · PubMed · Cited by 150
Epidemiology of EBV and Hodgkin's lymphoma
Jarrett, R. F., Armstrong, A. A., & Alexander, E. (1996) · Annals of Oncology · doi:10.1093/annonc/7.suppl_4.s5 · Cited by 149
Saltz, L. B., Kanowitz, J., Kemeny, N. E., Schaaf, L. J., Spriggs, D. R., Staton, B. A., Berkery, R., Steger, C., Eng, M., Dietz, A. B., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.11.2959 · Cited by 145
Yamashita, Y., Fujii, N., Murakata, C., Ashizawa, T., Okabe, M., & Nakano, H. (1992) · Biochemistry · doi:10.1021/bi00163a015 · Cited by 145
Tamura, H.-O., Kohchi, C., Yamada, R., Ikeda, T., Koiwai, O., Patterson, E., Keene, J. D., Okada, K., Kjeldsen, E., Nishikawa, K., et al. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.1.69 · Cited by 143
Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.
Verschraegen, C. F., Levy, T., Kudelka, A. P., Llerena, E., Ende, K., Freedman, R. S., Edwards, C. L., Hord, M., Steger, M., Kaplan, A. L., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.625 · Cited by 135
Saltz, L. B., Sirott, M. N., Young, C. W., Tong, W. P., Niedzwiecki, D., Tzy-Jyun, Y., Tao, Y., Trochanowski, B. J., Wright, P., Barbosa, K., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.18.1499 · Cited by 133
Rowinsky, E. K., Adjei, A. A., Donehower, R. C., et al. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.10.2193 · Cited by 130
Eng, W.-K., McCabe, F. L., Tan, K. B., et al. (1990) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09473-8 · Cited by 127
Phase I Study and Pharmacokinetics of CPT-11 With 5-Day Continuous Infusion
Ohe, Y., Sasaki, Y., Shinkai, T., Eguchi, K., Tamura, T., Kojima, A., Kunikane, H., Okamoto, H., Karato, A., Ohmatsu, H., et al. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.12.972 · Cited by 122
Rubin, E. H., Pantazis, P., Bharti, A. K., Toppmeyer, D., Giovanella, B. C., & Kufe, D. W. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41964-8 · Cited by 120
Yamashita, Y., Kawada, S., Fujii, N., & Nakano, H. (1991) · Biochemistry · doi:10.1021/bi00238a005 · Cited by 119
The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II
Larsen, A. K., Grondard, L., Couprie, J., Desoize, B., Comoë, L., Jc, J., & Riou, J. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90105-6 · Cited by 119
van der Zee, A. G. J., Hollema, H., de Jong, S., Boonstra, H., Gouw, A., Willemse, P. H. B., Zijlstra, J. G., & de Vries, E. G. E. (1991) · PubMed · Cited by 118
Madden, K. R., & Champoux, J. J. (1992) · PubMed · Cited by 112
Catimel, G., Chabot, G. G., Guastalla, J., Dumortier, A., Cote, C., Engel, C., Gouyette, A., Mathieu-Boué, A., Mahjoubi, M., & Clavel, M. (1995) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a059108 · Cited by 111
New Natural Products in Cancer Chemotherapy
Slichenmyer, W. J., & Hoff, D. D. V. (1990) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1990.tb01873.x · Cited by 109
Vassal, G., Terrier-Lacombe, M.-J., Bissery, M.-C., Vénuat, A. M., Gyergyay, F., Bénard, J., Morizet, J., Boland, I., Ardouin, P., Paillerets, B. B., et al. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.398 · Cited by 102
Yang, J. C., Horton, J. K., Cowan, K. H., & Schneider, E. (1995) · PubMed · Cited by 89
A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
Rubin, E. H., Wood, V., Bharti, A. K., Trites, D. H., Lynch, C., Hurwitz, S. J., Bartel, S. B., Levy, S., Rosowsky, A., & Toppmeyer, D. (1995) · PubMed · Cited by 87
In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues.
Emerson, D. L., Besterman, J. M., Brown, H. R., Evans, M. G., Leitner, P., Luzzio, M. J., Shaffer, J. E., Sternbach, D. D., Uehling, D., & Vuong, A. (1995) · PubMed · Cited by 77
Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine
Lokiec, F., Canal, P., Gay, C., Chatelut, É., Armand, J., Roche, H. H., Bugat, R., Gon�alv�s, E., & Mathieu-Bou�, A. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685737 · Cited by 75
Phase II study of topotecan in patients with recurrent malignant glioma
Macdonald, D., Cairncross, G., Stewart, D. J., Forsyth, P. A., Sawka, C., Wainman, N., & Eisenhauer, E. A. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010550 · Cited by 74
Danks, M. K., Garrett, K. E., Marion, R. C., & Whipple, D. O. (1996) · PubMed · Cited by 69
Natelson, E. A., Giovanella, B. C., Verschraegen, C. F., Fehir, K. M., de Ipolyi, P. D., HARRIS, N., & Stehlin, J. S. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb26392.x · Cited by 67
Yoshinari, T., Matsumoto, M., Arakawa, H., Okada, H., Noguchi, K., Suda, H., Okura, A., & Nishimura, S. (1995) · PubMed · Cited by 66
Mick, R., Gupta, E., Vokes, E. E., & Ratain, M. J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.2012 · Cited by 66
Induction of mammalian DNA topoisomerase I-mediated DNA cleavage and DNA winding by bulgarein
Fujii, N., Yamashita, Y., Saitoh, Y., & Nakano, H. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38632-6 · Cited by 63
Masuda, N., Fukuoka, M., Kudoh, S., Matsui, K., Kusunoki, Y., Takada, M., Nakagawa, K., Hirashima, T., Tsukada, H., & Yana, T. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.9.1833 · Cited by 61
Hinz, H. R., Harris, N. J., Natelson, E. A., & Giovanella, B. C. (1994) · PubMed · Cited by 58
Houghton, J. A., Cheshire, P. J., Hallman, J. D., Lutz, L., Luo, X., Li, Y., & Houghton, P. J. (1996) · PubMed · Cited by 50
Shimizu, T., & Pommier, Y. G. (1996) · Experimental Cell Research · doi:10.1006/excr.1996.0230 · Cited by 49
Phase II trial of topotecan in patients with advanced renal cell carcinoma
Law, T. M., Ilson, D. H., & Motzer, R. J. (1994) · Investigational New Drugs · doi:10.1007/bf00874445 · Cited by 42
Phase II study of topotecan in metastatic hormone-refractory prostate cancer
Hudes, G. R., Kosierowski, R., Greenberg, R., Ramsey, H. E., Fox, S. C., Ozols, R. F., McAleer, C. A., & Giantonio, B. J. (1995) · Investigational New Drugs · doi:10.1007/bf00873806 · Cited by 32
Cellular Resistance to Camptothecins
Pommier, Y. G., Gupta, M., Valenti, M., & Nieves‐Neira, W. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb26377.x · Cited by 31
Tolcher, A. W., O’Shaughnessy, J., Weiss, R. B., Zujewski, J. A., Myhand, R., Schneider, E., Hakim, F., GRESS, R. E., Goldspiel, B. R., Noone, M., et al. (1997) · PubMed · Cited by 27
Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors
Puc, H. S., Bajorin, D. F., Bosl, G. J., Amsterdam, A., & Motzer, R. J. (1995) · Investigational New Drugs · doi:10.1007/bf00872866 · Cited by 26
Standards for PBSC mobilisation and collection
Linch, D. C., & Watts, M. (1996) · Annals of Oncology · doi:10.1093/annonc/7.suppl_2.9 · Cited by 6
Cited by
DNA Topoisomerases: Structure, Function, and Mechanism
Champoux, J. J. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.369 · Cited by 2,743
Natural products as leads to anticancer drugs
Gordaliza, M. (2007) · Clinical and Translational Oncology · doi:10.1007/s12094-007-0138-9 · Cited by 701
Hetman, M., Kanning, K., Cavanaugh, J. E., & Xia, Z. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.32.22569 · Cited by 575
Bardia, A., Mayer, I. A., Diamond, J. R., Moroose, R. L., Isakoff, S. J., Starodub, A. N., Shah, N. C., O’Shaughnessy, J., Kalinsky, K., Guarino, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.8297 · Cited by 412
Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview
Vanhoefer, U., Harstrick, A., Achterrath, W., Cao, S., Seeber, S., & Rustum, Y. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1501 · Cited by 326
Metadata
- Authors
- Rothenberg, M. L.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 1997-08
- Volume
- 8
- Issue
- 9
- Pages
- 837-855
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2165351839
- Cited by
- 306
- References
- 79
- FWCI
- 6.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.